Engflag

Bromocriptine Mesylate

Quick links to important sections

Bromocriptine Mesylate

Selected form

Bromocriptine Mesylate_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bromocriptine Mesylate

Property Description
Active Ingredient Bromocriptine (as the methanesulfonate salt)
Form Oral Tablets and Capsules
Pharmacological Class Dopamine Agonist, Ergot Alkaloid Derivative
General Purpose Hormone regulation (e.g., Prolactin Inhibition) and enhancement of dopamine signaling
Origin Semisynthetic

Bromocriptine Mesylate is a prescription medication defined by its chemical composition and its primary function as a regulator of hormonal and neurological signaling within the body. It is classified as an Ergot Alkaloid Derivative and a Dopamine Agonist, designated for oral administration. The medicine's core mechanism allows it to mimic the action of the natural neurotransmitter dopamine.

Identity and Pharmacological Classification

Bromocriptine Mesylate is chemically the methanesulfonate salt of the active ingredient, Bromocriptine, a single-ingredient compound with a semisynthetic origin. It belongs to the Dopamine Agonist class, a group of drugs that directly stimulate dopamine receptors, notably the D2 and D3 subtypes, in the central nervous system and the pituitary gland. Bromocriptine Mesylate possesses dopaminergic and antiprolactinemic properties. The established class shows this medicine is designed to interact with crucial signaling pathways that regulate both movement and hormone levels.

Composition and Available Forms

The formulation contains the active ingredient, Bromocriptine, stabilized as the methanesulfonate salt, and is available as oral tablets and capsules. The semisynthetic origin means the compound is chemically derived from natural ergot alkaloids but modified to create a stable, pharmaceutically effective substance. Its availability in different solid dosage forms includes both standard release tablets and specialized quick-release formulations. This dual availability is a key differentiating factor, enabling the drug's core action to be utilized for varying therapeutic applications.

General Therapeutic Purpose

The fundamental purpose of this medication is to address certain physiological imbalances by enhancing dopamine signaling, primarily resulting in Prolactin Inhibition. By acting as a Dopamine Agonist, it suppresses the hypersecretion of prolactin from the pituitary gland. Bromocriptine Mesylate reduces plasma levels of prolactin. This action provides the general benefit of normalizing hormone levels where prolactin overproduction is an issue, and supports systems where dopamine activity requires enhancement, such as in motor control.

Regulatory References

  1. NIH StatPearls
  2. DailyMed - NIH

What side effects are possible with Bromocriptine Mesylate?

Possible Side Effects and Safety Information

Regulatory documentation structures the safety profile of Bromocriptine Mesylate by classifying adverse reactions based on frequency and the physiological system affected. The most Common effects documented include nausea, headache, dizziness, vomiting, constipation, and nasal congestion. Effects such as confusion, hallucinations, and orthostatic hypotension are classified as Uncommon.

System-Organ Classification of Adverse Reactions

Adverse effects are grouped into system-organ classes, with significant reporting in the Gastrointestinal Disorders (e.g., nausea, constipation), Nervous System Disorders (e.g., somnolence, headache), and Psychiatric Disorders (e.g., confusion, psychotic disorders). The label also notes effects on the Cardiovascular and Vascular systems (e.g., hypotension, arrhythmia).

Serious Adverse Reactions and Safety Patterns

The medicine is associated with a risk of serious, rare adverse reactions, particularly with high doses or long-term use. These include fibrotic complications such as pleural and pulmonary fibrosis, retroperitoneal fibrosis, and cardiac valvulopathy. Abruptly stopping the medication may be associated with a syndrome resembling Neuroleptic Malignant Syndrome.

Certain safety patterns are time-dependent: orthostatic hypotension is more likely upon treatment initiation or dose escalation, while sudden sleep onset and impulse control disorders (e.g., pathological gambling, hypersexuality) have also been reported. Regulatory notes advise caution for specific groups, including older adults, who may be more sensitive to neurological effects, and postpartum women, for whom close blood pressure monitoring is advised due to reports of cardiovascular events.

Overdose and Emergency Response

Overdose and When to Seek Help

If you believe you have taken too much Bromocriptine Mesylate, immediately contact a doctor or seek emergency medical attention at the nearest hospital. Acute overdose presentations typically involve gastrointestinal symptoms such as nausea and vomiting, alongside severe drops in blood pressure (hypotension). Other manifestations can include general fatigue, abnormal tiredness, confusion, somnolence, and fever.

Reported instances of acute ingestion of very large doses, up to 225 mg, were generally not associated with life-threatening reactions. However, overdose management is primarily supportive, with sympathomimetic agents (e.g., dopamine) potentially administered to treat severe hypotension.

Special Considerations for Urgent Medical Evaluation

While acute overdose is rarely life-threatening, urgent medical evaluation is critical for certain severe or developing symptoms, particularly in postpartum women. If you experience the following, stop taking the medication and seek help promptly:

  • Severe, progressive, or unremitting headache (with or without visual disturbances).
  • Evidence of Central Nervous System (CNS) toxicity, such as hallucinations, confusion, or seizures.
  • Sudden onset of severe hypertension or chest pain, as serious events including stroke and myocardial infarction have been reported in the postpartum population.

Therapeutic Uses of Bromocriptine Mesylate

What Bromocriptine Mesylate Treats: Main Uses and Benefits

The primary therapeutic applications of Bromocriptine Mesylate are focused on managing symptoms stemming from specific hormonal excesses and supporting neurological function.

This medication is commonly used across three main categories of conditions: those involving hyperprolactinemia (including prolactin-secreting pituitary tumors or prolactinomas), the core motor symptoms of Parkinson's disease, and systemic issues like Acromegaly and Type 2 Diabetes Mellitus.

It is used to ease the patient's symptomatic burden. “This treatment provides functional support that contributes to improved day-to-day comfort and stability during symptomatic periods.”

Management of Symptoms and Functional Support

For patients with hyperprolactinemia, the treatment may assist in easing associated symptoms such as the absence of menstrual periods (amenorrhea), abnormal milk discharge (galactorrhea), and issues related to infertility. For those with Parkinson's disease, it contributes to supporting functional stability by helping to ease manifestations like muscle rigidity and tremor. It is also applied as an adjunctive therapy for Type 2 Diabetes to support better glycemic control and to manage the systemic effects of hormonal excess in Acromegaly.

Quick Fact: Endocrine Support Bromocriptine Mesylate is considered relevant for managing conditions characterized by chronic, difficult-to-control manifestations stemming from specific hormonal excesses, offering support that helps ease the overall symptom load.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Bromocriptine Mesylate is subject to specific regulatory eligibility rules and contraindications that define which populations may or may not use the medicine.

Contraindicated Populations

The medicine must not be used by certain groups, as stated in official labeling:

  • Patients with known hypersensitivity to Bromocriptine or ergot alkaloids (ergot-related drugs).
  • Individuals with uncontrolled hypertension or a history of hypertensive disorders of pregnancy (including pre-eclampsia or eclampsia).
  • Postpartum women and those who are nursing/lactating.
  • Patients with syncopal migraine or a history of severe cardiovascular conditions (when treating non-life-threatening indications).

Restricted or Limited Use

Use is established for adults across all approved indications. However, caution or limitations apply to other groups:

  • Pediatric Patients: Safety and efficacy are not established for children younger than 7 years for any use.
  • Geriatric Patients: Use requires caution, as older patients may be more sensitive to the drug's effects.
  • Comorbidities: Caution is required for patients with hepatic impairment, severe psychiatric disorders (use is often not recommended), or a history of peptic ulcer disease.
  • Diabetes: The drug is not for Type 1 diabetes or diabetic ketoacidosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Bromocriptine Mesylate is structured by two key pharmacological activities: its metabolism by the CYP3A4 enzyme and its action as a dopamine receptor agonist. These factors determine specific constraints on co-administration with other medicines.

Interacting Product Category Official Regulatory Constraint Mechanistic Basis
Strong CYP3A4 Inhibitors (e.g., azole antimycotics, HIV protease inhibitors) Concomitant use must be avoided; requires adequate washout before initiation. Inhibition of metabolism increases bromocriptine circulating levels.
Moderate CYP3A4 Inhibitors (e.g., Erythromycin) Dose must be limited to 1.6 mg once daily. Inhibition of metabolism increases bromocriptine circulating levels.
Dopamine Receptor Antagonists (e.g., Neuroleptic/Antipsychotic Agents, Metoclopramide) Concomitant use is not recommended. Pharmacodynamic antagonism may diminish the effectiveness of both drugs.
Ergot-related Drugs (e.g., for migraine) Co-administration is not recommended within six hours of dosing. Potential for increased occurrence of ergot-related adverse effects.

Bromocriptine is also highly bound to serum proteins. Therefore, it may increase the unbound fraction of other co-administered, highly protein-bound therapies (such as salicylates or sulfonamides), which may alter their effectiveness or risk for side effects. Additionally, caution is advised when co-administering with antihypertensive medications due to the potential for symptomatic hypotension.

Mechanism of Action

The action of Bromocriptine Mesylate is primarily driven by its function as a dopamine agonist, leading to direct modulation of neuroendocrine and neurological signaling pathways.

Central D2 Agonism and Endocrine Regulation

Bromocriptine directly activates Dopamine D2 Receptors on lactotroph cells in the pituitary gland, initiating a molecular cascade that inhibits the adenylyl cyclase enzyme and reduces intracellular cAMP levels. This cellular suppression restricts both the synthesis and the release of the hormone prolactin, resulting in its systemic reduction.

Neurological Modulation and Systemic Effects

This activity extends to the central nervous system, where Bromocriptine stimulates D2 and D3 receptors in the nigrostriatal pathway. This interaction enhances dopaminergic neurotransmission in the pathways governing motor coordination. Furthermore, the molecule acts as an antagonist at peripheral alpha1-adrenergic receptors, introducing a secondary mechanism that affects vascular smooth muscle tone.

Dosage and Administration Information

Bromocriptine Mesylate is administered exclusively via the oral route in the form of tablets or capsules, and its use involves following labeled dosing schedules. The overall approach is a controlled titration, beginning with a low starting dose, such as 1.25 mg to 2.5 mg per day for the standard formulation, or 0.8 mg per day for the quick-release tablet. The dose is increased incrementally over specific time intervals, such as weekly or bi-weekly, until the therapeutic maintenance range is reached, which can vary from 2.5 mg up to 100 mg per day, depending on the indication.

A key principle of administration is the contextual timing. The medication is taken with food to support absorption and tolerability. Furthermore, the quick-release formulation used for Type 2 Diabetes has a requirement to be taken within two hours after waking in the morning. Specific administration protocols apply for certain populations; for older adults, dose selection typically starts at the lower end of the dosing range, and dose adjustment may be required for patients with hepatic impairment. In the event of a missed dose, the standard procedure is that the dose is skipped entirely and the regular schedule resumed, rather than doubling the dose. The two formulations—standard release and quick-release—are not interchangeable, and their use is specific to their designated applications, which structures the treatment protocol.

Recent Clinical Evidence

Bromocriptine Mesylate: Recent Clinical Evidence

Bromocriptine mesylate is an ergot derivative and a dopamine D2 receptor agonist. Clinical evidence supports its use for multiple conditions, including endocrinological, neurological, and metabolic disorders. The medication has distinct applications based on the formulation and indication.

Core Indications Supported by Trials

Early and sustained clinical trials established the efficacy of bromocriptine in managing conditions associated with hyperprolactinemia, such as amenorrhea (absence of menstruation), galactorrhea (abnormal milk discharge), and certain prolactin-secreting pituitary tumors (prolactinomas). Trial results indicate that the medication can reduce serum prolactin levels, often leading to symptom resolution and, in some cases, a measurable reduction in tumor size. The drug is also supported by evidence as an effective adjunct treatment for Parkinson's disease and acromegaly (excessive growth hormone production).

Clinical Findings in Type 2 Diabetes

A specific quick-release (QR) formulation of bromocriptine mesylate is also approved as an adjunct therapy for adults with Type 2 Diabetes Mellitus to improve glycemic control. Research in this area is focused on the drug's effect on central circadian neuronal activities within the hypothalamus, which may help reset elevated metabolic drivers. A large, 52-week clinical safety trial (n > 3000) was conducted to evaluate the cardiovascular safety profile of the QR formulation in this patient population, reporting a favorable safety profile concerning major adverse cardiovascular events.

Frequently Asked Questions (FAQ)

Common questions about Bromocriptine Mesylate (FAQ)

Q: How quickly should I expect to see an effect from Bromocriptine Mesylate for my condition?

Clinical studies and official label information describe that the time to observe a response can vary depending on the condition being treated. For conditions related to high prolactin levels, maximum hormone reduction is often observed within the first four weeks of starting therapy. While symptom changes may begin within days for some patients, others, such as those seeing the return of menstrual cycles, may take 6 to 8 weeks or longer.

Q: Are there any long-term side effects associated with Bromocriptine Mesylate use?

Regulatory documents note that some serious, rare adverse effects are associated with long-term, chronic use of medicines in this class (ergot derivatives). These effects involve fibrotic complications, which are described as a thickening or scarring of certain tissues. Regulatory documents mention these rare instances in the lungs, the lining of the chest cavity, and the space behind the abdomen (retroperitoneum).

Q: Is Bromocriptine Mesylate a controlled substance?

According to the official product information and the Drug Enforcement Administration (DEA), Bromocriptine Mesylate is not classified as a controlled substance under the Controlled Substances Act. This means the medicine is not regulated under the schedule system used for drugs with a potential for abuse or dependence.

Q: Can Bromocriptine Mesylate be used by people with kidney problems?

Official prescribing information generally states that a dosage adjustment is not usually necessary for patients with kidney (renal) impairment. However, official documentation advises caution for all patients, and eligibility for use should be determined by a healthcare provider.

Q: How long does Bromocriptine Mesylate stay in your system?

Official pharmacokinetic studies describe how the body processes the medicine. Data for the standard formulation indicate the elimination half-life is approximately 4.85 hours after a single oral dose. This value describes the measured time it takes for the concentration of the medicine in the bloodstream to be reduced by half.

Q: What does official guidance say about stopping Bromocriptine Mesylate?

Official warnings note that abruptly stopping the medication may be associated with a serious reaction known as a syndrome resembling Neuroleptic Malignant Syndrome (NMS). Due to this risk, any discontinuation should be conducted under the supervision of a healthcare professional.

Q: Should I avoid certain foods or vitamins while on Bromocriptine Mesylate?

Official drug interaction lists do not generally cite specific food or vitamin restrictions. The main administration instruction is to take the medicine with food to help reduce the possibility of stomach upset and support absorption. There are no known major interactions listed with common vitamins like Vitamin C.

Q: Is Bromocriptine Mesylate ever used in children?

The safety and effectiveness of the medication are generally not established for all children, particularly those younger than 7 years of age. Official prescribing information indicates that for prolactin-secreting pituitary adenomas, the standard formulation has an established therapeutic dosage range for children aged 11 to 15 years.

Q: Is Bromocriptine Mesylate a lifetime medication for some conditions?

The duration of use varies widely depending on the condition. Clinical data reviewed for conditions like pituitary tumors include studies of continuous use lasting over 1 to 10 years, establishing the medicine's role as a long-term therapeutic option.

Q: How is Bromocriptine Mesylate usually packaged?

According to the official product labels, the medication is typically dispensed in bottles containing a set number of tablets or capsules. The instructions emphasize that the medicine must be stored in the tight, light-resistant container it was dispensed in to protect it from heat and moisture.

Q: Is Bromocriptine Mesylate available as a generic drug?

Yes, Bromocriptine Mesylate is widely available as a generic drug. The U.S. Food and Drug Administration (FDA) has approved multiple generic versions of the tablets and capsules, establishing them as chemically equivalent to the brand name products.

Q: Has there been recent research on new uses for Bromocriptine Mesylate?

Yes, a specific quick-release formulation of the drug received official approval by the FDA in 2009 for a new, additional purpose. This formulation is approved as an adjunct therapy for adults with Type 2 Diabetes Mellitus to help improve blood sugar control.

How should Bromocriptine Mesylate be stored and disposed of?

How to Store and Dispose of Bromocriptine Mesylate

Bromocriptine mesylate must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). The medication must be kept in the tight, light-resistant container it was dispensed in and protected from excess heat, light, and moisture; storage in a bathroom is prohibited. To maintain safety, the medication must be stored out of the reach of children and kept in a secure, elevated location.

Disposal Requirements

Disposal of unused or expired bromocriptine mesylate should be managed through a drug take-back program or an authorized collection site, which is the preferred method. If household disposal is necessary, the product must not be flushed. Instead, mix the medication with an undesirable substance (such as used coffee grounds or dirt), seal the mixture in a container, and then place it in the trash. All personal information must be removed from the original container before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Bromocriptine Mesylate found in:

A-Z Index: